Search

Find exactly what you’re looking for.
Search

Service
Showing 61-80 of 165 results

We are Addicted to Purdue Pharma; You Should Be Too! Now that the US Supreme Court has agreed to hear the appeal filed by the US Trustee Program in Purdue Pharma bankruptcy, speculation is rife as to what decision will follow and how it will affect the use of nonconsensual third-party releases in...

Help, My Business is In Trouble! When a business becomes financially troubled, the business owner often experiences denial, paralysis, or both. Lenders commonly lose confidence and then trust in the business, as communications tend to break down, deadlines are missed, and promises are broken. Small...

The TMA Restructuring Boot Camp is an interactive, two-part program taught by TMA Certified Turnaround Professionals (CTPs) and attorneys. The TMA Restructuring Boot Camp is a high-level overview of what it's like to parachute into a simulated distressed company to uncover the financial, management...

​On June 27, 2023, the U.S. Supreme Court decided that states can require corporations registered in their state to consent to be sued in the state as a condition of doing business there—even if the facts of a lawsuit occurred several states away and the corporation is not "at home" in the state...

Appellate Practice: Celebrating 40 years at the Minnesota Court of Appeals Katie Barrett Wiik and co-panelist Jon Schmidt will discuss the rich history at the Minnesota Court of Appeals with the current Chief Judge and several former Chief Judges. - Jon Schmidt; Assistant Hennepin County Attorney –...

Saul Ewing LLP, a full-service national law firm, is proud to announce that Bankruptcy & Restructuring Practice Vice Chair Monique B. DiSabatino was selected as one of Law360's 2023 Rising Stars. Editors reviewed more than 1,300 submissions for the Rising Star distinction, which recognizes top...

​On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...

For More Information
Contact us